Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 14/20 | 1.00 |
| ▸ | CDK2 | P24941 | 14/20 | 1.00 |
| ▸ | CCNK | O75909 | 14/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 14/20 | 1.00 |
| ▸ | CDK7 | P50613 | 14/20 | 1.00 |
| ▸ | CCNH | P51946 | 14/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 12/20 | 1.00 |
| ▸ | CDK9 | P50750 | 12/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 12/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25597252 | 1.00 | CCNE1 (1.00) | CCNE1CDK2CCNKCDK12CDK7 | |
| SCHEMBL30203920 | 1.00 | CCNE1 (1.00) | CCNE1CDK2CCNKCDK12CDK7 | |
| SCHEMBL24839778 | 0.90 | CCNE1 (1.00) | CCNE1CDK2CCNKCDK12CDK7 | |
| SCHEMBL30204413 | 0.90 | CCNE1 (1.00) | CCNE1CDK2CCNKCDK12CDK7 | |
| SCHEMBL25263660 | 0.85 | CCNK (1.00) | CCNE1CDK2CCNKCDK12CDK7 | |
| SCHEMBL25329327 | 0.84 | CDK7 (0.89) | CCNE1CDK2CCNKCDK12CDK7 | |
| SCHEMBL25329325 | 0.84 | CDK7 (0.89) | CCNE1CDK2CCNKCDK12CDK7 | |
| SCHEMBL22115126 | 0.84 | CDK7 (1.00) | CCNE1CDK2CCNKCDK12CDK7 | |
| SCHEMBL29498451 | 0.84 | CDK7 (1.00) | CCNE1CDK2CCNKCDK12CDK7 | |
| SCHEMBL21188808 | 0.83 | CCNK (0.76) | CCNE1CDK2CCNKCDK12CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-01-05 | — | — | US | disclosed |
| US-20210401859-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2021-12-30 | — | — | US | disclosed |
| US-10738067-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200190126-A1 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, RB1, MKI67 | CCNE1 54/4885CDK2 20/4885CCNK 10/4885 |
| US-10738067-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK1, CDK17 | CCNE1 45/4885CDK2 5/4885CCNK 8/4885 |
| US-20210401859-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK4, RB1 | CCNE1 34/4885CDK2 14/4885CCNK 13/4885 |
| US-20200190126-A1 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) | CDK7, CDK1, CDK17 | CCNE1 45/4885CDK2 5/4885CCNK 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.